In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain. Never miss a story ...

This goal is what motivates scientists at NervGen Pharma Corporation, a clinical-stage biotechnology company dedicated to developing innovative treatments to enable nervous system repair in the ...

Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025 Vancouver, British Columbia--(Newsfile Corp. - May 15, 2025) - NervGen Pharma Corp. (TSXV ...

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology was licensed from Case Western Reserve University ...

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative ...

NervGen Pharma Corp. operates as a clinical stage biotech company. It provides development of treatment that enables the nervous system to repair itself following damage, whether due to injury or ...

Vancouver, British Columbia--(Newsfile Corp. - May 7, 2025) - NervGen Pharma Corp. (NGEN:CA) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...